BRPI0717219A2 - "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica." - Google Patents

"composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."

Info

Publication number: BRPI0717219A2
Authority: BR; Brazil
Prior art keywords: immunogenic composition; treating; preventing disease; immunogenic; disease
Prior art date: 2006-10-12

Application number

BRPI0717219-2A

Other languages

English (en)

Inventor

William Ripley Ballou

Jr.

Emmanuel Jules Hanon

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-12

Filing date

2007-10-10

Publication date

2015-05-26

2006-10-12 Priority claimed from GBGB0620336.8A external-priority patent/GB0620336D0/en

2006-10-12 Priority claimed from GB0620337A external-priority patent/GB0620337D0/en

2006-10-19 Priority claimed from GB0620815A external-priority patent/GB0620815D0/en

2006-10-19 Priority claimed from GB0620816A external-priority patent/GB0620816D0/en

2006-12-20 Priority claimed from PCT/EP2006/069977 external-priority patent/WO2007071710A2/en

2007-04-20 Priority claimed from GB0707697A external-priority patent/GB0707697D0/en

2007-06-12 Priority claimed from GB0711357A external-priority patent/GB0711357D0/en

2007-06-21 Priority claimed from GB0712062A external-priority patent/GB0712062D0/en

2007-10-10 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2015-05-26 Publication of BRPI0717219A2 publication Critical patent/BRPI0717219A2/pt

2021-01-19 Publication of BRPI0717219B1 publication Critical patent/BRPI0717219B1/pt

2021-05-25 Publication of BRPI0717219B8 publication Critical patent/BRPI0717219B8/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Virology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

BRPI0717219A 2006-10-12 2007-10-10 composição imunogênica, e, uso de uma composição imunogênica BRPI0717219B8 (pt)

Applications Claiming Priority (15)

Application Number	Priority Date	Filing Date	Title
GB0620336.8		2006-10-12
GBGB0620336.8A GB0620336D0 (en)	2006-10-12	2006-10-12	Vaccine
GB0620337A GB0620337D0 (en)	2006-10-12	2006-10-12	Vaccine
GB0620337.6		2006-10-12
GB0620816.9		2006-10-19
GB0620815A GB0620815D0 (en)	2006-10-19	2006-10-19	Vaccine
GB0620816A GB0620816D0 (en)	2006-10-19	2006-10-19	vaccine
GB0620815.1		2006-10-19
PCT/EP2006/069977 WO2007071710A2 (en)	2005-12-22	2006-12-20	Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
PCT/EP2006/069979 WO2007071711A2 (en)	2005-12-22	2006-12-20	Vaccine
GB0707697A GB0707697D0 (en)	2007-04-20	2007-04-20	Vaccine
GB0711357A GB0711357D0 (en)	2007-06-12	2007-06-12	Vaccine
GB0711357.4		2007-06-12
GB0712062A GB0712062D0 (en)	2007-06-21	2007-06-21	Vaccine
PCT/EP2007/060743 WO2008043774A1 (en)	2006-10-12	2007-10-10	Vaccine comprising an oil in water emulsion adjuvant

Publications (3)

Publication Number	Publication Date
BRPI0717219A2 true BRPI0717219A2 (pt)	2015-05-26
BRPI0717219B1 BRPI0717219B1 (pt)	2021-01-19
BRPI0717219B8 BRPI0717219B8 (pt)	2021-05-25

Family

ID=40551582

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0717219A BRPI0717219B8 (pt)	2006-10-12	2007-10-10	composição imunogênica, e, uso de uma composição imunogênica

Country Status (18)

Country	Link
US (2)	US20100183667A1 (pt)
JP (2)	JP5230632B2 (pt)
KR (1)	KR101151202B1 (pt)
CN (1)	CN101522218B (pt)
AU (1)	AU2007306381B2 (pt)
BR (1)	BRPI0717219B8 (pt)
CA (1)	CA2664619C (pt)
CR (1)	CR10726A (pt)
DK (1)	DK2086582T3 (pt)
EA (1)	EA015817B1 (pt)
ES (1)	ES2397714T3 (pt)
HR (1)	HRP20130023T1 (pt)
IL (1)	IL197512A (pt)
MA (1)	MA30866B1 (pt)
MX (1)	MX2009003325A (pt)
NO (1)	NO20091022L (pt)
PT (1)	PT2086582E (pt)
WO (1)	WO2008043774A1 (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2371994C (en) *	1999-02-26	2010-09-28	Guido Grandi	Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
DE10144906B4 (de)	2001-09-12	2013-11-28	Novartis Vaccines And Diagnostics Gmbh	Verfahren zur großtechnischen Herstellung von Impfstoffen
AR054020A1 (es)	2005-03-23	2007-05-30	Glaxosmithkline Biolog Sa	Nuevo uso
MX2009000660A (es)	2006-07-17	2009-04-08	Glaxosmithkline Biolog Sa	Vacuna de influenza.
EA015817B1 (ru) *	2006-10-12	2011-12-30	Глаксосмитклайн Байолоджикалс С.А.	Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
UA99719C2 (ru)	2006-11-03	2012-09-25	Шеринг-Плау Лтд.	Вакцина для собак против болезни лайма
PE20090146A1 (es) *	2007-04-20	2009-03-23	Glaxosmithkline Biolog Sa	Composicion inmunogenica contra el virus influenza
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
JP5518041B2 (ja)	2008-03-18	2014-06-11	ノバルティスアーゲー	インフルエンザウイルスワクチン抗原の調製における改良
ES2553113T3 (es) *	2008-04-16	2015-12-04	Glaxosmithkline Biologicals S.A.	Vacuna
JP2011516597A (ja) *	2008-04-16	2011-05-26	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
KR101443064B1 (ko)	2008-08-28	2014-09-19	노파르티스 아게	과-생산 효모 유래 스쿠알렌의 제조
WO2010032138A2 (en)	2008-09-18	2010-03-25	Novartis Ag	Vaccine adjuvant combinations
EP3173097A3 (en) *	2009-02-10	2017-07-12	Seqirus UK Limited	Influenza vaccines with reduced amounts of squalene
CA2752041A1 (en)	2009-02-10	2010-08-19	Novartis Ag	Influenza vaccines with increased amounts of h3 antigen
EA201171032A1 (ru)	2009-02-10	2012-02-28	Новартис Аг	Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
PE20110992A1 (es)	2009-02-17	2012-02-12	Glaxosmithkline Biolog Sa	Composicion inmunogenica que comprende un antigeno del virus del dengue
EP3017826A1 (en)	2009-03-24	2016-05-11	Novartis AG	Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP3263128A3 (en)	2009-04-14	2018-01-24	GlaxoSmithKline Biologicals S.A.	Compositions for immunising against staphylococcus aureus
EA021009B1 (ru)	2009-05-21	2015-03-31	Новартис Аг	ОБРАТНАЯ ГЕНЕТИКА С ИСПОЛЬЗОВАНИЕМ НЕЭНДОГЕННЫХ ПРОМОТОРОВ pol I
CN104862335A (zh)	2009-07-31	2015-08-26	诺华股份有限公司	反向遗传系统
GB0918392D0 (en)	2009-10-20	2009-12-02	Novartis Ag	Diagnostic and therapeutic methods
CA2778332A1 (en)	2009-10-20	2011-04-28	Novartis Ag	Improved reverse genetics methods for virus rescue
GB0919117D0 (en)	2009-10-30	2009-12-16	Glaxosmithkline Biolog Sa	Process
GB0919690D0 (en)	2009-11-10	2009-12-23	Guy S And St Thomas S Nhs Foun	compositions for immunising against staphylococcus aureus
BR112012018669A2 (pt)	2010-01-27	2017-09-05	Glaxosmithkline Biologicals Sa	Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
AU2011288203A1 (en)	2010-03-18	2012-08-23	Novartis Ag	Adjuvanted vaccines for serogroup B meningococcus
NZ603918A (en)	2010-05-12	2015-04-24	Novartis Ag	Improved methods for preparing squalene
CN103025350A (zh)	2010-05-21	2013-04-03	诺华有限公司	流感病毒的重配方法
GB201009861D0 (en)	2010-06-11	2010-07-21	Novartis Ag	OMV vaccines
WO2012117377A1 (en)	2011-03-02	2012-09-07	Novartis Ag	Combination vaccines with lower doses of antigen and/or adjuvant
EP2768528A1 (en)	2011-10-20	2014-08-27	Novartis AG	Adjuvanted influenza b virus vaccines for pediatric priming
WO2013088367A1 (en)	2011-12-12	2013-06-20	Novartis Ag	Assay for influenza virus hemagglutinins
CN104023744A (zh)	2011-12-23	2014-09-03	诺华股份有限公司	用于针对金黄色葡萄球菌免疫的稳定组合物
CN103608453B (zh)	2012-03-02	2018-07-24	思齐乐	流感病毒重配
MX372965B (es)	2012-03-08	2020-04-01	Glaxosmithkline Biologicals Sa	Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
US20150203543A1 (en)	2012-08-31	2015-07-23	Novartis Ag	Stabilised proteins for immunising against staphylococcus aureus
HUE044211T2 (hu)	2012-08-31	2019-10-28	Glaxosmithkline Biologicals Sa	Staphylococcus aureus elleni immunizálásra szolgáló, stabilizált fehérjék
JP6324961B2 (ja)	2012-09-06	2018-05-16	ノバルティスアーゲー	血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
GB201218195D0 (en)	2012-10-10	2012-11-21	Istituto Zooprofilattico Sperimentale Delle Venezie	Composition
EP2906239A1 (en)	2012-10-12	2015-08-19	GlaxoSmithKline Biologicals SA	Non-cross-linked acellular pertussis antigens for use in combination vaccines
CN111249455A (zh)	2012-11-30	2020-06-09	葛兰素史密丝克莱恩生物有限公司	假单胞菌抗原和抗原组合
KR20150110494A (ko)	2012-12-03	2015-10-02	노파르티스 아게	재배열 인플루엔자 a 바이러스
WO2014086787A1 (en)	2012-12-05	2014-06-12	Glaxosmithkline Biologicals S.A.	Immunogenic composition
US20150320852A1 (en)	2012-12-18	2015-11-12	Glaxosmithkline Biologicals Sa	Conjugates for protecting against diphtheria and/or tetanus
SG11201507454XA (en)	2013-03-13	2015-10-29	Novartis Ag	Influenza b virus reassortment
EP2976107B1 (en) *	2013-03-19	2019-02-20	ASIT BioTech s.a.	Allergen preparation
SG11201509265SA (en)	2013-05-10	2015-12-30	Novartis Ag	Avoiding narcolepsy risk in influenza vaccines
SI3542819T1 (sl) *	2013-05-14	2021-11-30	Zoetis Services Llc	Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide
DE202013005100U1 (de)	2013-06-05	2013-08-26	Novartis Ag	Influenza Virus Reassortierung
DE202013005130U1 (de)	2013-06-05	2013-09-10	Novartis Ag	Influenza Virus Reassortierung
CN105722976A (zh)	2013-06-06	2016-06-29	诺华股份有限公司	流感病毒重配
BR112016015835B1 (pt)	2014-01-21	2023-12-26	Pfizer Inc	Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
CN106103469B (zh)	2014-03-26	2020-11-27	葛兰素史密丝克莱恩生物有限公司	突变型葡萄球菌抗原
MX2016015241A (es) *	2014-05-26	2017-10-11	Becton Dickinson France	Metodo para almacenar una vacuna emulsionada con adyuvante en un dispositivo de inyeccion medical lubricado.
US10238739B2 (en)	2014-12-02	2019-03-26	Novartis Ag	Manufacture of surfactant-containing compositions with enhanced stability
KR102790570B1 (ko)	2015-07-07	2025-04-04	세퀴러스 유케이 리미티드	인플루엔자 효능 검정
BE1024160B9 (fr)	2015-12-22	2017-12-06	Glaxosmithkline Biologicals Sa	Formulation immunogène
CN109982715A (zh)	2016-09-27	2019-07-05	免疫疫苗技术有限公司	利用低剂量体积b细胞表位组合物以在受试人中诱导抗体免疫应答的方法
CN106511996B (zh) *	2016-11-04	2019-09-10	江苏省农业科学院	用于口蹄疫疫苗的复乳型佐剂及其制备方法
CN110225757A (zh)	2017-01-31	2019-09-10	默沙东公司	由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
CN109652384B (zh) *	2019-02-21	2021-10-26	昆明理工大学	一种体外培养戊型肝炎病毒的方法
EP4061930A1 (en)	2019-11-18	2022-09-28	Seqirus Pty Ltd	Method for producing reassortant influenza viruses
KR20210117832A (ko) *	2020-03-20	2021-09-29	강원대학교산학협력단	Gla-se를 포함하는 수족구병 백신 조성물
WO2022002783A1 (en)	2020-06-29	2022-01-06	Glaxosmithkline Biologicals Sa	Adjuvants
MX2023002356A (es)	2020-08-24	2023-03-22	Sanofi Pasteur Inc	Vacunas contra la covid-19 con coadyuvantes en emulsion de escualeno que contiene tocoferol.
US20240165224A1 (en)	2021-03-26	2024-05-23	Glaxosmithkline Biologicals Sa	Immunogenic compositions
WO2023020994A1 (en)	2021-08-16	2023-02-23	Glaxosmithkline Biologicals Sa	Novel methods
WO2023020993A1 (en)	2021-08-16	2023-02-23	Glaxosmithkline Biologicals Sa	Novel methods
WO2023020992A1 (en)	2021-08-16	2023-02-23	Glaxosmithkline Biologicals Sa	Novel methods
KR102901149B1 (ko) *	2022-09-05	2025-12-17	주식회사 차백신연구소	에멀전 제형의 면역증강제 조성물 및 이의 제조 방법
CN120346163A (zh) *	2024-01-22	2025-07-22	中国科学院过程工程研究所	水包油乳液

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2905287A1 (de)	1979-02-12	1980-08-21	Siemens Ag	Verfahren zur automatischen elektrochemischen endpunktsbestimmung einer titration
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4454119A (en)	1981-06-29	1984-06-12	Mitsubishi Chemical Industries Limited	Therapeutic agents
FI69639C (fi) *	1982-07-02	1986-03-10	Orion Yhtymae Oy	Preparat foer anvaendning vid klamydia-diagnostik
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
FI861417A0 (fi)	1985-04-15	1986-04-01	Endotronics Inc	Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
EP0362278A4 (en)	1987-06-05	1990-05-14	Us Health	Autocrine motility factors in cancer diagnosis and management.
US4940460A (en)	1987-06-19	1990-07-10	Bioject, Inc.	Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
EP1088830A3 (en)	1987-06-22	2004-04-07	Medeva Holdings B.V.	Hepatitis b surface antigen particles
US5339163A (en)	1988-03-16	1994-08-16	Canon Kabushiki Kaisha	Automatic exposure control device using plural image plane detection areas
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
GB8819209D0 (en)	1988-08-12	1988-09-14	Research Corp Ltd	Polypeptide & dna encoding same
US4999403A (en)	1988-10-28	1991-03-12	Exxon Chemical Patents Inc.	Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
WO1990006951A1 (en)	1988-12-16	1990-06-28	De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur	Pneumolysin mutants and pneumococcal vaccines made therefrom
ATE115862T1 (de)	1989-02-04	1995-01-15	Akzo Nobel Nv	Tocole als impfstoffadjuvans.
CA2017507C (en)	1989-05-25	1996-11-12	Gary Van Nest	Adjuvant formulation comprising a submicron oil droplet emulsion
EP0414374B1 (en)	1989-07-25	1997-10-08	Smithkline Biologicals S.A.	Novel antigens and methods for their preparation
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
GB9118204D0 (en)	1991-08-23	1991-10-09	Weston Terence E	Needle-less injector
AU2927892A (en)	1991-11-16	1993-06-15	Smithkline Beecham Biologicals (Sa)	Hybrid protein between cs from plasmodium and hbsag
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US5569189A (en)	1992-09-28	1996-10-29	Equidyne Systems, Inc.	hypodermic jet injector
US5334144A (en)	1992-10-30	1994-08-02	Becton, Dickinson And Company	Single use disposable needleless injector
US5776468A (en)	1993-03-23	1998-07-07	Smithkline Beecham Biologicals (S.A.)	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5688506A (en)	1994-01-27	1997-11-18	Aphton Corp.	Immunogens against gonadotropin releasing hormone
WO1995024176A1 (en)	1994-03-07	1995-09-14	Bioject, Inc.	Ampule filling device
US5466220A (en)	1994-03-08	1995-11-14	Bioject, Inc.	Drug vial mixing and transfer device
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US5599302A (en)	1995-01-09	1997-02-04	Medi-Ject Corporation	Medical injection system and method, gas spring thereof and launching device using gas spring
JP3958360B2 (ja)	1995-02-24	2007-08-15	キャンタブファーマシューティカルズリサーチリミティド	免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en)	1995-10-10	1998-03-24	Visionary Medical Products Corporation, Inc.	Gas pressured needle-less injection device and method
US5843464A (en)	1995-06-02	1998-12-01	The Ohio State University	Synthetic chimeric fimbrin peptides
US5666153A (en)	1995-10-03	1997-09-09	Virtual Shopping, Inc.	Retractable teleconferencing apparatus
US5893397A (en)	1996-01-12	1999-04-13	Bioject Inc.	Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en)	1996-04-11	1996-06-12	Weston Medical Ltd	Spring-powered dispensing device
CA2253549C (en)	1996-06-18	2005-10-25	Alza Corporation	Device for enhancing transdermal agent delivery or sampling
US20030133944A1 (en) *	2001-04-05	2003-07-17	Smithkline Beecham Biologicals S.A.	Vaccine composition against malaria
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
EP0957972B1 (en)	1996-12-20	2003-03-19	Alza Corporation	Device and method for enhancing transdermal agent flux
WO1998050567A1 (en)	1997-05-02	1998-11-12	Abbott Laboratories	Reagents and methods useful for detecting diseases of the prostate
US5993412A (en)	1997-05-19	1999-11-30	Bioject, Inc.	Injection apparatus
EP0998557A2 (en)	1997-07-21	2000-05-10	North American Vaccine, Inc.	Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9717953D0 (en)	1997-08-22	1997-10-29	Smithkline Beecham Biolog	Vaccine
AU1145699A (en)	1997-09-05	1999-03-22	Smithkline Beecham Biologicals (Sa)	Oil in water emulsions containing saponins
GB9718901D0 (en)	1997-09-05	1997-11-12	Smithkline Beecham Biolog	Vaccine
US7459524B1 (en)	1997-10-02	2008-12-02	Emergent Product Development Gaithersburg Inc.	Chlamydia protein, sequence and uses thereof
EP2218731A1 (en)	1997-11-28	2010-08-18	Merck Serono Biodevelopment	Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
CA2312900A1 (en)	1997-12-02	1999-06-10	Powderject Vaccines, Inc.	Transdermal delivery of particulate vaccine compositions
IT1298087B1 (it)	1998-01-08	1999-12-20	Fiderm S R L	Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
PL202844B1 (pl)	1998-04-07	2009-07-31	Corixa Corp	Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu
US6319224B1 (en)	1999-08-20	2001-11-20	Bioject Medical Technologies Inc.	Intradermal injection system for injecting DNA-based injectables into humans
GB9923176D0 (en) *	1999-09-30	1999-12-01	Smithkline Beecham Biolog	Novel composition
US6494865B1 (en)	1999-10-14	2002-12-17	Becton Dickinson And Company	Intradermal delivery device including a needle assembly
JP2001316251A (ja) *	2000-02-24	2001-11-13	Fuairudo Kk	炭素燃焼残査の超微粒子を含むスクワラン及びその製造方法
GB0025577D0 (en) *	2000-10-18	2000-12-06	Smithkline Beecham Biolog	Vaccine
EP1455700A4 (en)	2001-11-16	2007-02-14	3M Innovative Properties Co	METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
AR054020A1 (es) *	2005-03-23	2007-05-30	Glaxosmithkline Biolog Sa	Nuevo uso
NZ594482A (en) *	2005-11-04	2012-11-30	Novartis Vaccines & Diagnostic	Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
EA015817B1 (ru)	2006-10-12	2011-12-30	Глаксосмитклайн Байолоджикалс С.А.	Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
PE20090146A1 (es) *	2007-04-20	2009-03-23	Glaxosmithkline Biolog Sa	Composicion inmunogenica contra el virus influenza

2007
- 2007-10-10 EA EA200900350A patent/EA015817B1/ru not_active IP Right Cessation
- 2007-10-10 CA CA2664619A patent/CA2664619C/en active Active
- 2007-10-10 HR HRP20130023TT patent/HRP20130023T1/hr unknown
- 2007-10-10 PT PT78211117T patent/PT2086582E/pt unknown
- 2007-10-10 JP JP2009531831A patent/JP5230632B2/ja active Active
- 2007-10-10 KR KR1020097009716A patent/KR101151202B1/ko not_active Expired - Fee Related
- 2007-10-10 WO PCT/EP2007/060743 patent/WO2008043774A1/en not_active Ceased
- 2007-10-10 US US12/445,090 patent/US20100183667A1/en not_active Abandoned
- 2007-10-10 ES ES07821111T patent/ES2397714T3/es active Active
- 2007-10-10 CN CN200780038231XA patent/CN101522218B/zh active Active
- 2007-10-10 AU AU2007306381A patent/AU2007306381B2/en not_active Ceased
- 2007-10-10 BR BRPI0717219A patent/BRPI0717219B8/pt not_active IP Right Cessation
- 2007-10-10 DK DK07821111.7T patent/DK2086582T3/da active
- 2007-10-10 MX MX2009003325A patent/MX2009003325A/es active IP Right Grant
2009
- 2009-03-10 NO NO20091022A patent/NO20091022L/no not_active Application Discontinuation
- 2009-03-10 IL IL197512A patent/IL197512A/en active IP Right Grant
- 2009-04-17 CR CR10726A patent/CR10726A/es not_active Application Discontinuation
- 2009-05-06 MA MA31843A patent/MA30866B1/fr unknown
2012
- 2012-12-13 JP JP2012272452A patent/JP5767201B2/ja active Active
2015
- 2015-01-09 US US14/593,911 patent/US9700605B2/en active Active

Also Published As

Publication number	Publication date
MA30866B1 (fr)	2009-11-02
AU2007306381A1 (en)	2008-04-17
CR10726A (es)	2009-05-25
JP5767201B2 (ja)	2015-08-19
DK2086582T3 (da)	2013-02-04
AU2007306381B2 (en)	2011-12-08
IL197512A (en)	2013-10-31
KR101151202B1 (ko)	2012-06-11
US20100183667A1 (en)	2010-07-22
CA2664619A1 (en)	2008-04-17
US9700605B2 (en)	2017-07-11
CN101522218A (zh)	2009-09-02
MX2009003325A (es)	2009-04-09
PT2086582E (pt)	2013-01-25
KR20090066323A (ko)	2009-06-23
JP5230632B2 (ja)	2013-07-10
BRPI0717219B8 (pt)	2021-05-25
JP2010505907A (ja)	2010-02-25
EA200900350A1 (ru)	2009-10-30
IL197512A0 (en)	2011-08-01
EA015817B1 (ru)	2011-12-30
CA2664619C (en)	2012-12-11
HRP20130023T1 (hr)	2013-02-28
BRPI0717219B1 (pt)	2021-01-19
US20150359863A1 (en)	2015-12-17
WO2008043774A1 (en)	2008-04-17
JP2013067646A (ja)	2013-04-18
ES2397714T3 (es)	2013-03-08
CN101522218B (zh)	2012-09-26
NO20091022L (no)	2009-04-27

Legal Events

Date	Code	Title	Description
2016-06-14	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-20	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-16	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-11-17	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-01-19	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/10/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2021-09-08	B15V	Prolongation of time limit allowed
2025-08-05	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 18A ANUIDADE.
2025-11-25	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2848 DE 05-08-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0717219A2 (pt)	2015-05-26	"composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0810956A2 (pt)	2015-09-08	"composição, método para controlar de modo preventivo ou curativo e uso da composição"
BRPI0910963A2 (pt)	2016-01-05	composição imunogênica, método para tratar ou prevenir doença pneumocócica, e , uso de uma composição imunogênica
BRPI0717697A2 (pt)	2016-03-22	composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BRPI0907663A2 (pt)	2015-07-21	''composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições.
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0916235A2 (pt)	2018-03-13	composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
BRPI0911203A2 (pt)	2016-07-05	peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0820568A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BRPI0814957A2 (pt)	2015-02-03	Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0916693A2 (pt)	2017-07-04	uso de uma quantidade eficaz de pelo menos um microorganismo probiótico, composição cosmética e/ou dermatológica, e, método de tratamento cosmético
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0612274A2 (pt)	2016-09-06	lipase, uso de uma lipase ou uma mistura de lípases, composição farmacêutica, e, método para o tratamento de uma doença
BRPI0717753A2 (pt)	2013-10-22	Método de tratamento ou redução do risco de uma doença causada por protozoários, e, composição.
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0911350A2 (pt)	2017-12-05	conjugado de polietileno glicol, método para tratar hemofilia b, e, método para reduzir o risco de doenças ou condições.
BRPI0820967A2 (pt)	2015-07-14	Uso de uma composição, composição farmacêutica e método para tratamento, melhora ou profilaxia dos sintomas de uma doença inflamatória
CL2007002920A1 (es)	2008-06-06	Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.